Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
Condition(s):Geographic Atrophy; Dry Age Related Macular DegenerationLast Updated:June 22, 2010Completed
Hide Studies Not Open or Pending
Condition(s):Geographic Atrophy; Dry Age Related Macular DegenerationLast Updated:June 22, 2010Completed
Condition(s):Geographic AtrophyLast Updated:March 12, 2024Recruiting
Condition(s):Macular Degeneration, Age-Related; Geographic AtrophyLast Updated:March 27, 2024Terminated
Condition(s):Geographic Atrophy; Macular DegenerationLast Updated:April 23, 2019Terminated
Condition(s):Age Related Macular DegenerationLast Updated:December 14, 2020Unknown status
Condition(s):Geographic AtrophyLast Updated:January 20, 2014Terminated
Condition(s):Macular Degeneration; Geographic AtrophyLast Updated:November 24, 2023Active, not recruiting
Condition(s):Geographic AtrophyLast Updated:March 19, 2024Recruiting
Condition(s):Age Related Macular Degeneration; Geographic AtrophyLast Updated:January 20, 2014Completed
Condition(s):Dry Age-related Macular Degeneration; Geographic Atrophy; Gene Therapy; Intravitreal InjectionLast Updated:May 10, 2021Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.